Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTX325 in Healthy Volunteers and Parkinson's Disease
NCT07630545Phase 1Recruiting
- Sponsor
- Mission Therapeutics
- Start
- Nov 2023
- Primary completion
- Jun 2027
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of MTX325 in Parkinson's disease (PD) (4 arms), sponsored by Mission Therapeutics. Primary endpoints: Safety and Tolerability at 28 days and Brain Biodistribution at 1 day. Started Nov 2023; status: recruiting.
02
Drugs
MTX325
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07630545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07630545.